Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
(9h)
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
(11h)
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
(14h)
BioPharma Dive
BIO unveils plan for US to remain biotech’s ‘global leader’
(1h)
Bayer wins FDA nod for a new kind of blood thinner
(7h)
Vir hepatitis D drug succeeds in first pivotal study
(13h)
Endpoints News
Bayer wins FDA approval for stroke prevention drug Sunharbo
(6h)
How early efforts to build autonomous clinical AI tools are approaching regulation
(9h)
Trump’s drug pricing deals force tough choices on launches
(10h)
BioSpace
BioSpace 2027 Best Places to Work shines light on most admired employers
(1h)
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
(11h)
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
(11h)
STAT News
Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
(5h)
FDA approves novel Bayer drug to reduce recurrence of stroke
(7h)
Trump administration removes WuXi AppTec from its Chinese military list
(9h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(10h)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(5d)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(5d)
Drug Channels
BlinkRx Insights: Clarifying the Mystery around “DTP”
(3d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(4d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(6d)
European Biotechnology Magazine
Immunocore doubles up on T-cell engagers in eye cancer
(13h)
argenx buys macrocycle partner Unnatural Products for up to $1.15 billion
(22h)
CDMO: How to find a reliable partner
(1d)
Drug Hunter
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(14h)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(15h)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(3d)
Labiotech.EU
Zooming out from ovaries: how has renaming PMOS changed lives?
(3d)
How to turn a BIO-Europe meeting into a lasting partnership
(3d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(5d)
Bio IT World
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(23m)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(3d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(5d)
GEN News
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(6h)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(9h)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(16h)
Cure Today
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(8h)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(10h)
Rural Lung Cancer: Only 36% of Medicare Patients Had Gene Testing
(14h)
Contract Pharma
Spruce Bio Spins CAH Program Off into New Subsidiary Adrenyx
(8h)
Pluri CDMO Business Adds Two ISO Certifications
(14h)
Charles River to Acquire Frontage’s Bioanalysis, DPMK Businesses
(15h)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Medcity News
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(6h)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(8h)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(8h)
Chemical & Engineering News
Comment: To NOBCChE, community is everything
(5h)
Chemistry in Pictures: Golden tears
(10h)
Mitsui Chemicals will acquire JSR in electronic materials push
(11h)
The Pharma Letter
Pierre Fabre and XtalPi ink discovery AI-driven collaboration
(13h)
Adneuris files cebranopadol NDA for acute pain, pitching lower abuse potential than oxycodone
(13h)
Almirall nine-month sales up 8.3% as Ebglyss surges 75% and EBITDA climbs 22.7%
(16h)
Targeted Oncology
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
(8h)
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
(10h)
Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care
(11h)
MedWatch
Ambu board seeks sharp increase in executive bonus caps
(17h)
Demant goes on offensive with US veterans: “We aim to steadily expand our position”
(17h)
Trustee to seek disqualification of former Audientes management
(19h)
In The Pipeline
Jon Clardy, 1943-2026
(9h)
Antimicrobial Peptides for Fun (?) and Profit (?)
(4d)
The Morning After the Midterms
(5d)
Pharmaphorum
Amazon puts $100m into global health drive
(16h)
MHRA grants Innovation Passports to three novel drugs
(17h)
argenx agrees Unnatural takeover deal worth up to $1.15bn
(18h)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(1w)
Why we need to rethink childhood cancer treatments
(1w)
Q3 UK biotech VC heads for record year thanks to megadeals
(1w)
HIT Consultant
AWS Launches $100M Health Impact Initiative to Scale Agentic and Cloud Tech in Underserved Global Care
(13h)
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics
(14h)
Reclaiming $44.9B in Hospital Uncompensated Care via Automated Upfront Eligibility
(15h)
Insights: Pink Sheet
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(2h)
Korea Streamlines Review Of Digital Convergence Combos
(3h)
US FDA Probes Tumor Risk With Novartis’ Zolgensma And Itvisma After Gene Integration Reports
(5h)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(2d)
Standardization, not customization: A site-CRO perspective on trial quality
(8h)
Survey finds women are willing to join trials, yet rarely invited
(11h)
BioCentury
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(3d)
Post-election pricing outlook: stormy with a chance of compromise
(3d)
Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report
(3d)
SCRIP
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
(1h)
Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
(7h)
ACR 2026: A Tale Of Three Cell Therapies
(8h)